派姆单抗治疗伴有中枢神经系统累及的难治性原发性纵隔 B 细胞淋巴瘤。
Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.
机构信息
Department of Hematology, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Spain.
MRI Unit, Institut de Diagnòstic per la Imatge, Hospital Germans Trias i Pujol, Badalona, Spain.
出版信息
Hematol Oncol. 2021 Aug;39(3):419-422. doi: 10.1002/hon.2836. Epub 2021 Jan 11.
Primary mediastinal large B-cell lymphoma (PMBCL) is a rare aggressive B-cell lymphoma characterized by the frequent presence of amplification and translocation events at 9p24.1, resulting in the expression of the programmed cell death-1 (PD-1) ligands PD-L1 and PD-L2. Pembrolizumab, a humanized anti-PD-1 monoclonal antibody, binds PD-1 and blocks this interaction, enhancing the activity of the immune system against tumor cells, and has shown activity in PMBCL and in some cases of primary and secondary central nervous system (CNS) lymphoma. We report the case of a 40-year-old woman diagnosed with relapsed PMBCL and secondary CNS involvement who responded to pembrolizumab monotherapy, allowing for a later allogeneic stem cell transplant.
原发性纵隔大 B 细胞淋巴瘤（PMBCL）是一种罕见的侵袭性 B 细胞淋巴瘤，其特征是 9p24.1 频繁出现扩增和易位事件，导致程序性细胞死亡受体 1（PD-1）配体 PD-L1 和 PD-L2 的表达。派姆单抗是一种人源化抗 PD-1 单克隆抗体，可与 PD-1 结合并阻断这种相互作用，从而增强免疫系统对肿瘤细胞的活性，已在 PMBCL 和某些原发性和继发性中枢神经系统（CNS）淋巴瘤中显示出活性。我们报告了一例 40 岁女性复发性 PMBCL 和继发性中枢神经系统受累的病例，该患者对派姆单抗单药治疗有反应，随后进行了同种异体干细胞移植。
Zotero 插件